Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269670 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Everolimus Beyond Progression
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02269670: Clinical Trial Phase 2 study, sponsored by Emory University.
NCT02269670 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02269670, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chemotherapy drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are hormones that can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by lowering the amount of estrogen and progesterone the body makes. Giving everolimus with a different type of hormone therapy may be an effective treatment for breast cancer in patients who progressed on everolimus with exemestane.
Primary Outcome
Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.
Interventions
- DRUG letrozole
- DRUG fulvestrant
- DRUG everolimus
- DRUG anastrozole
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-11-25 |
| Est. Completion | 2021-01-25 |
| Phase | Phase 2 |
Why NCT02269670 stopped before completion
NCT02269670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which letrozole is the first listed.
NCT02269670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02269670 about?
NCT02269670 is a clinical study titled "Phase II Study of Everolimus Beyond Progression". This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chem...
What is the current status of trial NCT02269670?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-11-25. Estimated completion is 2021-01-25.
What interventions are being tested in trial NCT02269670?
The interventions under investigation include: letrozole (DRUG), fulvestrant (DRUG), everolimus (DRUG), anastrozole (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT02269670?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02269670's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI